Genome-edited Cells
Liver
The SNHG17 Knockout Hep-G2 Cell Line offers a CRISPR/Cas9-edited loss-of-function model in human hepatocellular carcinoma cells. This product enables targeted disruption of the oncogenic lncRNA SNHG17, which promotes liver cancer through ceRNA-mediated regulation of miRNAs and downstream targets. SNHG17, activated by SP1, STAT3, and c-MYC, sponges miR-338-3p, miR-186-5p, and miR-485-5p to upregulate SOX4, ZEB1, and Cyclin D1, driving PI3K/AKT and Wnt/??-catenin signaling. The knockout cell line is ideal for proliferation, migration, invasion, and apoptosis assays, supporting research in ceRNA networks, drug target validation, and biomarker discovery.
CDPF1 Knockout jurkat Polyclonal Cells
Cat. No. ARG12823
MAPKAPK2 Knockout A549 Polyclonal Cells
Cat. No. ARG10296
KHDRBS1 Knockout NCI-H1975 Polyclonal Cells
Cat. No. ARG31832
IAH1 Knockout HAP1 Polyclonal Cells
Cat. No. ARG27587
NPEPL1 Knockout A549 Polyclonal Cells
Cat. No. ARG9958
CNDP2 Knockout HEK293T Polyclonal Cells
Cat. No. ARG4179
The SNHG17 Knockout Hep-G2 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from Homo sapiens hepatocellular carcinoma Hep-G2 cells. This loss-of-function model enables targeted disruption of the SNHG17 long non-coding RNA gene, providing a reliable system for investigating its roles in cancer. The cell line is maintained under standard culture conditions, ready for functional genomics and signaling studies.
The Hep-G2 host cell line originates from a liver biopsy of a 15-year-old male with hepatocellular carcinoma. These epithelial cells retain key hepatic functions, including drug metabolism and hepatotoxicity responses, making them a widely used model for liver biology. Hep-G2 cells express relevant cytochrome P450 enzymes and respond to genotoxic and metabolic stresses, offering a physiologically relevant context for studying hepatic carcinogenesis and compound safety.
SNHG17 functions as an oncogenic lncRNA that drives tumor cell proliferation, migration, and invasion primarily through a ceRNA mechanism. Upstream transcription factors SP1, STAT3, and c-MYC activate its expression. SNHG17 sponges tumor-suppressive miRNAs such as miR-338-3p, miR-186-5p, and miR-485-5p, thereby derepressing targets like SOX4, ZEB1, Cyclin D1, and Bcl-2. This network converges on PI3K/AKT and Wnt/??-catenin signaling, with representative components PIK3CA, AKT1, mTOR, CTNNB1, and TCF4, as well as EMT regulators CDH1, VIM, and SNAI1.
In Hep-G2 cells, SNHG17 knockout attenuates oncogenic signaling and allows dissection of lncRNA-mediated tumor progression. Loss of SNHG17 is anticipated to reduce PI3K/AKT and Wnt/??-catenin pathway activity, impair migration and invasion, and alter apoptosis and cell cycle profiles. This model facilitates validation of miRNA-lncRNA interactions and EMT regulation, and it can be used to evaluate whether Hep-G2 tumorigenicity depends on SNHG17.
The cell line supports multiple functional assays: MTT/CCK-8 proliferation, colony formation, wound healing, Transwell migration/invasion, flow cytometry for apoptosis and cell cycle, RT-qPCR, and Western blot for targets like Cyclin D1 and ZEB1. Dual luciferase reporter assays confirm miRNA interactions. Applications include lncRNA functional studies, ceRNA network investigation, drug target validation, and biomarker discovery in liver cancer. For further inquiries, contact Ascent Research.
